subject inclusion question in replicate design for ANVISA [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2019-09-04 20:23 (868 d 04:23 ago) – Posting: # 20542
Views: 1,827

Hi Shuanghe,

» […] the client's statistical consultant commented that only subjects who complete all 4 period (2T+2R) should be included, otherwise, they should be excluded even if they completed 3 period.

IMHO, this doesn’t make sense. See the example in the vignette of replicateBE. At least this is what I have I done in my European studies and never got a question about it.

» By the way, Helmut, does this belong to Study Assessment or Regulative/Guideline category?

Study Assessment is about ongoing/completed studies. I moved it here.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,831 posts in 4,567 threads, 1,553 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Wednesday 23:47 CET (Europe/Vienna)

Research under a paradigm must be a particularly effective way
of inducing paradigm change.    Thomas S. Kuhn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5